Monopar and NorthStar to develop radio therapies for severe COVID-19

Monopar Therapeutics (MNPR +10.7%) and NorthStar Medical Radioisotopes announce 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19.

Monopar and NorthStar plan to couple MNPR-101, a pre-IND humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody, to a therapeutic radioisotope in order to create selective agent that has the potential to kill aberrantly activated cytokine-producing immune cells, hence mitigate the cytokine storm and reduce deaths associated with COVID-19

https://seekingalpha.com/news/3583507-monopar-and-northstar-collaborate-to-develop-rits-for-severe-covidminus-19-treatment